GLP-1s and Osteoporosis: What the Research Actually Shows
We all have seen just how quickly GLP-1 medications (such as Ozempic and Wegovy) have been adopted in treating obesity and type 2 diabetes. Almost everyone knows someone taking these drugs, and the widespread use of these drugs has raised important questions about the relationship between bone health and weight loss.
As millions of people begin taking these medications, researchers are asking an important question: Do GLP-1 medications affect bone density? Can Ozempic or Wegovy increase your risk of osteoporosis?
The precise answer is still being debated, but a growing body of research suggests that rapid weight loss, regardless of how it is achieved, deserves careful attention from a bone health perspective. Recently, we attended the Interdisciplinary Symposium on Osteoporosis, hosted by the Bone Health and Osteoporosis Foundation, and sat in on many talks on the possible relationships between these new drugs and osteoporosis.
Why Does Rapid Weight Loss Affect Bone Density?
We have long known in the bone health research world that weight loss is associated with bone loss, regardless of whether it comes from diet, bariatric surgery, illness, or medications.
A comprehensive 2025 review published in Bone Research describes weight loss as "a significant risk factor for compromised skeletal integrity." The authors explain that while moderate weight loss can “yield metabolic benefits,” rapid or sustained weight loss is "frequently associated with decreased bone mineral density, deterioration of bone microarchitecture, and heightened fracture risk."
Why would weight loss be associated with greater risk of fracture? The authors explain that weight loss changes the amount of force placed on the skeleton, alters hormones involved in bone remodeling, reduces nutrient intake, and shifts the body's energy metabolism.
One of the simplest explanations is that our skeleton adapts to the amount of weight it carries. As the review explains, bone is "a mechanosensitive organ that relies heavily on continuous mechanical stimulation to maintain its structure and function."
When body weight decreases, bones experience less mechanical loading, leading to less stimulation for new bone formation. Not surprisingly, researchers have found that the more weight people lose, the more bone density they tend to lose as well. According to the review, meta-analyses consistently show that bone mineral density loss is proportional to the amount of body weight lost, particularly at the hip and femoral neck, two of the most common sites for osteoporotic fractures.
The encouraging news is that bone loss is not inevitable. The same review concludes that exercise training remains "the most effective and evidence-supported strategy" to restore the mechanical forces that help maintain healthy bones. Another good reason to combine exercise and diet in any pursuit of weight loss.
Can GLP-1 Medications Cause Bone Loss?
We know that, broadly, weight loss is associated with bone loss. Specifically, however, researchers are still trying to determine whether any changes in bone are caused by the medications themselves or by the rapid weight loss they produce. This is an important distinction considering some 10 million Americans are now taking GLP-1s.
One interesting development occurred at the 2026 American Academy of Orthopaedic Surgeons Annual Meeting. There, researchers presented data from more than 146,000 adults with obesity and type 2 diabetes who were followed for five years. Compared with people who were not taking GLP-1 medications, users experienced a modestly higher rate of osteoporosis, along with small increases in gout and osteomalacia, a condition characterized by soft bones.
Lead investigator Dr. John Horneff shared that these medications have important benefits, but also pointed out that many patients "start to decrease their intake of food and nutrients." Because appetite suppression is one of the primary ways these medications promote weight loss, some people may unintentionally consume less calcium, protein, vitamin D, and other nutrients essential for maintaining healthy bones.
Horneff also urged perspective when interpreting the findings. The increase in osteoporosis risk, he said, "It's not huge," although the researchers did observe "nearly a doubling of the risk of having some sort of bone mineral density issue at five years."
Dr. Clifford Rosen, professor of medicine at Tufts University and co-author of the recent Bone Research review, places these findings in a broader context in a recent NBC article. He puts it plainly, "Weight loss does cause bone loss." The question researchers are now trying to answer is "whether this is a normal compensation of the skeleton... or whether this is truly a risk for losing bone that's more rapid than what would be expected."
Taken together, these findings suggest that the conversation should not focus solely on whether GLP-1 medications affect bone directly. Instead, clinicians and patients should think more broadly about protecting bone during periods of rapid weight loss.
What Does the FDA Say About Wegovy and Fracture Risk?
The Food and Drug Administration does not state that Wegovy causes osteoporosis. However, the official prescribing information includes an observation from one of its largest clinical trials that deserves attention:
"In the cardiovascular outcomes trial, patients aged 75 years and older reported more fractures of the hip and pelvis on WEGOVY than on placebo."
This observation does not establish that Wegovy caused the fractures, but it reinforces the importance of paying attention to bone health, particularly in older adults who are already at elevated risk for osteoporosis. “Paying attention” here means monitoring bone mineral density via a DEXA scan, ensuring you’re eating a calcium-rich diet, consuming adequate vitamin D, and getting regular exercise.
Who Is Most at Risk for Bone Loss on a GLP-1?
Although research is ongoing, some groups may need to pay particular attention to bone health. While anyone losing weight should think about protecting their bones, certain people may be at higher risk while taking a GLP-1 medication. This includes postmenopausal women, adults over age 65, people who already have osteopenia or osteoporosis, individuals who are not getting enough calcium or protein, those experiencing rapid weight loss, and anyone who is not regularly performing resistance or weight-bearing exercise.
How Can You Protect Your Bones While Taking a GLP-1?
Current evidence suggests that protecting bone health during GLP-1 therapy means protecting bone health during weight loss in general.
That includes consuming enough calcium, vitamin D, and high-quality protein, maintaining muscle mass through regular resistance and weight-bearing exercise, and discussing bone density testing with your healthcare provider if you have additional risk factors for osteoporosis.
Dr. Christopher McGowan, an obesity medicine specialist, summarized the evidence well. Lifestyle, he says, "play[s] a major role." That's why he recommends that treatment with GLP-1 medications include "guidance on protein intake, exercise and bone health monitoring."
Current research does not show that everyone taking Ozempic, Wegovy, or similar mediations will develop osteoporosis. However, it does suggest that rapid weight loss and bone health deserve careful attention.
The emerging evidence points toward a comprehensive approach: lose weight if medically appropriate, but protect your skeleton at the same time. Consuming adequate calcium (especially dietary calcium!), protein, and vitamin D, performing regular resistance exercise, and discussing bone health with your healthcare provider can all help reduce the risk of bone loss during treatment.
